Inovio Pharmaceuticals, Inc. (INO) News
Follow Inovio Pharmaceuticals, Inc. (INO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 28 public stories across 11 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Inovio Q3'26 Earnings Preview: EPS Estimate at (0.20) USD
Inovio is set to report Q3'26 results November 10 after the market closes. Revenue is estimated at USD 0, with EPS expected at (0.20) USD.
EQUITY | Nov 09, 2026, 12:01 PM UTC
L
Inovio Pharma: Jefferies and Piper Sandler Are Acting as Joint Book-Running Managers for the Offering >INO
Inovio Pharma: Jefferies and Piper Sandler Are Acting as Joint Book-Running Managers for the Offering >INO
EQUITY | Nov 05, 2026, 09:12 PM UTC
L
INOVIO Announces Proposed Public Offering of its Common Stock
PLYMOUTH MEETING, Pa., Nov. 5, 2026 // -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related dise
EQUITY | Nov 05, 2026, 09:01 PM UTC
L
Form SCHEDULE 13G/A INOVIO PHARMACEUTICALS, Filed by: FMR LLC
Filed on: November 5, 20
EQUITY | Nov 05, 2026, 06:21 PM UTC
M
INOVIO to Report Third-Quarter 2026 Results November 10
INOVIO said it will report its third-quarter 2026 financial results on November 10, 2026.
EQUITY | Nov 02, 2026, 09:19 PM UTC
H
Inovio shares surge 186% after FDA approves rare-disease treatment
Inovio Pharmaceuticals shares surged 186% after the FDA approved a treatment for a rare respiratory condition.
REGULATION | Nov 02, 2026, 02:45 PM UTC
M
Inovio Presents Accelerated FDA Approval of VOCERYQ
Inovio presents accelerated FDA approval of VOCERYQ for adults with RRP.
REGULATION | Nov 02, 2026, 02:10 PM UTC
M
Inovio Wins FDA Accelerated Approval for VOCERYQ
Inovio received FDA accelerated approval for VOCERYQ to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis.
REGULATION | Nov 02, 2026, 12:23 PM UTC
M
FDA Grants Accelerated Approval to Inovio’s VOCERYQ
The FDA approved the immunotherapy to reduce surgery frequency in adults with recurrent respiratory papillomatosis.
REGULATION | Nov 02, 2026, 10:57 AM UTC
M
Inovio Gets FDA Nod for Rare Throat Disease
Shares of Inovio Pharmaceuticals jump after an FDA nod for a rare throat disease.
REGULATION | Nov 02, 2026, 10:48 AM UTC
M
FDA Approves Inovio Treatment; Shares More Than Triple Premarket
The FDA approved an Inovio treatment for a rare respiratory condition. Inovio shares more than tripled premarket.
REGULATION | Nov 02, 2026, 09:14 AM UTC
M
INOVIO Wins $80.4 Million Judgment in VGXI/GeneOne Case
INOVIO secured a $80.4 million judgment, including $61.8 million in damages and $18.7 million in fees. The company warned that the defendants’ financial condition will likely impair collection.
EQUITY | Oct 20, 2026, 08:06 PM UTC
L
INO: INO-3107 nears FDA decision, backed by strong trial data and commercial launch preparations
A proprietary DNA medicines platform is advancing toward potential approval with INO-3107 for RRP, showing strong efficacy and safety in trials. Commercial readiness is high, with a focused market strategy and robust pip
REGULATION | Sep 09, 2026, 09:12 PM UTC
L
INO: INO-3107 shows strong efficacy for RRP, with FDA decision and commercialization plans imminent
The discussion highlighted a proprietary DNA medicines platform with a lead candidate, INO-3107, nearing a pivotal FDA decision for RRP. Strong clinical efficacy, a favorable safety profile, and commercial readiness posi
REGULATION | Sep 09, 2026, 08:24 PM UTC
L
INO - INOVIO to Participate in Upcoming Investor Conferences
INO - INOVIO to Participate in Upcoming Investor Conferences
EQUITY | Sep 01, 2026, 08:06 PM UTC
L
INO Reports Q2 2026 Financial Results
INO reports second quarter 2026 financial results and recent business highlights
EARNINGS | Aug 12, 2026, 08:06 PM UTC
L
INO INO - INOVIO to Report Second Quarter Financial Results on August 12, 2026
INO INO - INOVIO to Report Second Quarter Financial Results on August 12, 2026
EARNINGS | Aug 04, 2026, 08:05 PM UTC
H
Nasdaq Surges Over 600 Points; Microsoft Shares Jump After Upbeat Q4 Results
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 600 points on Thursday. Following the market opening Thursday, the Dow traded up 0.69% to 51,951.16 while the NASDAQ surged 2.54% to 25,
EARNINGS | Jul 30, 2026, 02:05 PM UTC
L
Deals priced today • JMKE (Jersey Mike’s Subs) 43.48M share IPO, priced at $23.00 (range was $21 - $25), by MSCO, JEFF, JPMC, BARC, GUGG, BA
Deals priced today • JMKE (Jersey Mike’s Subs) 43.48M share IPO, priced at $23.00 (range was $21 - $25), by MSCO, JEFF, JPMC, BARC, GUGG, BAML, GSCO, Evercore, UBS, B*ird, WELLS, WBLR, Nomura, Piper, RAJA, Stifel, TD, BT
EQUITY | Jul 30, 2026, 12:04 PM UTC
L
Multiple Companies: File Forms
Multiple companies file forms with regulators
FX | Jul 30, 2026, 09:42 AM UTC
H
Why Microsoft Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket
Shares of Microsoft Corp (NASDAQ: MSFT ) rose sharply in pre-market trading after the company reported better-than-expected fourth-quarter financial results. Microsoft reported fourth-quarter revenue of $90.01 billion, u
EARNINGS | Jul 30, 2026, 08:30 AM UTC
L
Multiple Companies File Forms
Multiple companies file forms with regulators
FX | Jul 30, 2026, 04:17 AM UTC
M
INOVIO prices $20M public offering
INOVIO prices public offering
EQUITY | Jul 30, 2026, 12:54 AM UTC
L
INO Inovio announces common stock and warrants offering, no amount given
INO Inovio announces common stock and warrants offering, no amount given
EQUITY | Jul 29, 2026, 08:05 PM UTC
H
Inovio Proposes Public Offering
Inovio proposes public offering
EQUITY | Jul 29, 2026, 08:01 PM UTC
L
Inovio Pharmaceuticals Files $300 Million Mixed Shelf Offering
() -- Inovio Pharmaceuticals (INO) filed a shelf registration to offer up to $300 million in a mix of securities, including common and preferred stock, debt securities, and warrants. Proceeds may be used for working capi
EQUITY | Jul 02, 2026, 09:19 PM UTC
L
Inovio Pharmaceuticals May Offer Up To $300 Mln Of Securities
Sec Filing
REGULATION | Jul 02, 2026, 08:09 PM UTC
L
WHO Director-General Ghebreyesus Says He Considers The Cruise Ship-Linked Hantavirus Outbreak To Be Over
WHO Director-General Ghebreyesus Says He Considers The Cruise Ship-Linked Hantavirus Outbreak To Be Over
EQUITY | Jul 02, 2026, 01:18 PM UTC